Daniel C. Martin - 16 Jun 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Commercial Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Jun 2022
Net transactions value
-$14,093
Form type
4
Filing time
21 Jun 2022, 16:35:58 UTC
Previous filing
18 Feb 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $14,093 -1,311 -2.6% $10.75 49,521 16 Jun 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock.
F2 Includes 2,164 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2022.